Anavex Life Sciences Corp (OTCMKTS:AVXL) a clinical-stage biopharmaceutical firm working on lead drug candidates to cure Alzheimer’s and other CNS diseases presented latest promising preclinical data for both ANAVEX 3-71 and ANAVEX 2-73. The data was highlighted in two separate presentations at the International Conference 2015 on ‘Alzheimer’s and Parkinson’s Diseases’ and associated Neurological Disorders in France.
The presentation
Tangui Maurice, PhD who is a member of the Scientific Advisory Board of Anavex verified for the first time the vital role of S1R through S1R Knock out on memory and survival in the presence of amyloid. At present, ANAVEX 2-73 is undergoing a Phase 2a study in patients suffering from Alzheimer after concluding a Phase 1 trial with a clean data profile. In previous preclinical trials, ANAVEX 2-73 reflected potential to reverse or stop Alzheimer’s disease. In addition, positive preclinical results disclose the potential for ANAVEX 2-73 as a lead drug to cure additional CNS disorders.
ANAVEX 3-71
The second presentation was on ANAVEX 3-71 which was previously named as AF710B. it is a promising and unique preclinical drug candidate with an innovative mechanism of action demonstrated to improve cognition and neuroprotection in Alzheimer. It can be stated as CNS-penetrable mono treatment that bridges cure of both cognitive impairments along with disease modifications. There are several beneficial effects including reduction of inflammation and mitochondrial dysfunctions.
The management view
Anavex’s CEO Christopher U. Missling, PhD said that with the last presented data the company is encouraged to have the two drugs currently in the clinic and expects to update on the progress of the ongoing study next quarter. The drug candidate ANAVEX 3-71 indicates broad therapeutic benefits in Alzheimer’s disease provided its ability to increase neuroprotection and cognition via SIR activation.
In last trading session, Anavex stock price surged 4.29% to close at $0.219 at volume of 403,530.
